---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical presentation - signs and symptoms"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical presentation - signs and symptoms. Topics: Asymptomatic course: detection by imaging or liver chemistries; Physician-reported signs and symptoms survey: US adults with MASH, 2019 and 2022; Constitutional symptoms: fatigue, sleep disturbance, and general weakness; Fatigue and pruritus: adults with bridging fibrosis or compensated cirrhosis due to NASH, STELLAR 3 and 4 baseline; 6 further topics. 10 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/clinical-presentation-signs-and-symptoms"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical presentation - signs and symptoms

<a id="heading-2.2.1.6"></a>

## 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

### Asymptomatic course: detection by imaging or liver chemistries

> “In most patients, NAFLD is asymptomatic or associated with vague symptoms, often leaving patients undiagnosed.”
> “Patients with NAFLD are most commonly referred with incidentally noted hepatic steatosis on imaging or elevated liver chemistries.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

> “Unless specific testing is done to identify NAFLD, the condition is typically silent until advanced and potentially irreversible liver impairment occurs. For this reason, the majority of patients with NAFLD are unaware of having this serious condition.”

Source: [Duell et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35418240/)

> “MASH is commonly symptomatic only during later stages of the disease and symptoms can be highly non-specific, making diagnosis challenging for physicians.”

Source: [Shinde et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12519272/)

<a id="topic-2.2.1.6-2"></a>

### Physician-reported signs and symptoms survey: US adults with MASH, 2019 and 2022

> “We assessed work productivity burden in a real-world population with suspected/confirmed MASH, comparing work productivity and symptoms across subgroups (risk status, age, BMI, and comorbidities) in the USA using secondary data from Adelphi Real World MASH Disease Specific Programmes™, cross-sectional surveys of physicians and consulting patients in 2019 and 2022.”
> “Fourteen prespecified individual physician-reported features of MASH were evaluated by the survey: fatigue, sleep disturbance, insomnia, general weakness, unexplained weight loss, hair loss, changes to personality, memory loss, jaundice, aching/discomfort in upper right abdomen, itchy skin, swelling in the legs/ankles/feet, tendency to bleed and bruise more easily, and swelling of the abdomen.”
> “These risk categories were: low-risk MASH (liver biopsy fibrosis stages F0–2, VCTE <8.0 kPa; FIB-4 <1.3); indeterminate (liver biopsy n/a, VCTE >8.0–12.0 kPa; FIB-4 n/a); and high-risk MASH (liver biopsy fibrosis stages F3–4, VCTE >12 kPa; FIB-4 ≥1.3).”
> “Of the 14 reported signs and symptoms, 11 were significantly associated with both physician-stated fibrosis stage and/or AASLD-derived risk category.”

Source: [Shinde et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12519272/)

| Physician-reported sign or symptom, n (%) | Overall (n = 424) | AASLD-derived low risk (n = 141) | AASLD-derived indeterminate risk (n = 30) | AASLD-derived high risk (n = 82) |
| --- | --- | --- | --- | --- |
| None | “167 (39.4)” | “58 (41.1)” | “6 (20.0)” | “9 (11.0)” |

Source: [Shinde et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12519272/)

<a id="topic-2.2.1.6-3"></a>

### Constitutional symptoms: fatigue, sleep disturbance, and general weakness

| Physician-reported sign or symptom, n (%) | Overall (n = 424) | AASLD-derived low risk (n = 141) | AASLD-derived indeterminate risk (n = 30) | AASLD-derived high risk (n = 82) |
| --- | --- | --- | --- | --- |
| Fatigue | “230 (54.2)” | “71 (50.4)” | “22 (73.3)” | “70 (85.4)” |
| Sleep disturbance | “100 (23.6)” | “27 (19.1)” | “8 (26.7)” | “39 (47.6)” |
| Insomnia | “37 (8.7)” | “13 (9.2)” | “3 (10.0)” | “11 (13.4)” |
| General weakness | “68 (16.0)” | “19 (13.5)” | “6 (20.0)” | “29 (35.4)” |

Source: [Shinde et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12519272/)

> “Non-specific symptoms of fatigue, sleep disturbance, and general weakness associated with MASH and other conditions predicted work impact in low-risk MASH.”

Source: [Shinde et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12519272/)

> “Data were drawn from the Adelphi Real World MASH Disease Specific Programme™, a cross-sectional survey of physicians and patients with MASH in Canada, France, Germany, and Italy between January 2024 and June 2024.”
> “In all patients, fatigue was the most reported symptom (48.1%, n = 1,268/2,636) followed by sleep disturbance (25.3%, n = 667/2,636), and general weakness (23.7%, n = 625/2,636; Table S3).”

Source: [Marquardt et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13019595/)

<a id="topic-2.2.1.6-4"></a>

### Fatigue and pruritus: adults with bridging fibrosis or compensated cirrhosis due to NASH, STELLAR 3 and 4 baseline

> “Specifically, PROs (Short Form–36, Chronic Liver Disease Questionnaire–NASH, Euro‐Qol 5 Dimension, and Work Productivity and Activity Impairment instruments) were assessed at baseline in patients with histologically confirmed bridging fibrosis (F3) or compensated cirrhosis (F4) due to NASH enrolled in STELLAR 3 and 4.”
> “Among the included 1,669 patients with advanced NASH (mean age = 58 ± 9 years, 48% F3, 42% with psychiatric comorbidities), 33% and 27% had fatigue and pruritus, respectively.”
> “The median pruritus score was 6 (interquartile range [IQR] 4‐7) and did not differ between patients with bridging fibrosis and compensated cirrhosis (P = 0.55).”
> “Conclusion: Clinically significant fatigue and pruritus are common in patients with advanced NASH, and these symptoms negatively affect PROs.”

Source: [Younossi et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7603531/)

<a id="topic-2.2.1.6-5"></a>

### Fatigue, pruritus, and sleep disorders: adults with MASLD in the Global NAFLD/MASLD Registry

> “Patients with MASLD were prospectively enrolled into the Global NAFLD/MASLD Registry.”
> “A total of 8034 patients with MASLD from 39 countries (age 54±12 years, 46% male, 50% type 2 diabetes, 39% advanced fibrosis) were included. At baseline, 25% reported significant pruritus, 35% significant fatigue, and 34% sleep disorders, and 10% had all 3 symptoms.”
> “At 1-year follow-up, over half of the patients with baseline symptoms continued to experience them, and 14% to 18% developed de novo symptoms.”

Source: [Younossi et al. (2026c)](https://pubmed.ncbi.nlm.nih.gov/42925568/)

<a id="topic-2.2.1.6-6"></a>

### Abdominal and skin symptoms: right upper quadrant discomfort, pruritus, and jaundice

> “MASH has been associated with symptoms such as fatigue, abdominal pain, and poor sleep quality.”

Source: [Shinde et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12519272/)

| Physician-reported sign or symptom, n (%) | Overall (n = 424) | AASLD-derived low risk (n = 141) | AASLD-derived indeterminate risk (n = 30) | AASLD-derived high risk (n = 82) |
| --- | --- | --- | --- | --- |
| Aching/discomfort in upper right abdomen | “43 (10.1)” | “15 (10.6)” | “2 (6.7)” | “23 (28.0)” |
| Itchy skin | “35 (8.3)” | “13 (9.2)” | “5 (16.7)” | “10 (12.2)” |
| Jaundice | “14 (3.3)” | “3 (2.1)” | “1 (3.3)” | “8 (9.8)” |

Source: [Shinde et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12519272/)

<a id="topic-2.2.1.6-7"></a>

### Cognitive symptoms: memory loss and changes to personality

> “Obesity and cognitive impairment are also common in individuals with MASH.”

Source: [Shinde et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12519272/)

| Physician-reported sign or symptom, n (%) | Overall (n = 424) | AASLD-derived low risk (n = 141) | AASLD-derived indeterminate risk (n = 30) | AASLD-derived high risk (n = 82) |
| --- | --- | --- | --- | --- |
| Memory loss | “11 (2.6)” | “3 (2.1)” | “0 (0.0)” | “7 (8.5)” |
| Changes to personality | “9 (2.1)” | “4 (2.8)” | “0 (0.0)” | “4 (4.9)” |

Source: [Shinde et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12519272/)

> “Patients were grouped as: early fibrosis (stage 0–2) without additional CVRM comorbidities (EFnoC); early fibrosis with additional CVRM comorbidities (EFwC); or advanced fibrosis (stage 3–4) with additional CVRM comorbidities (AFwC).”
> “Patients with AFwC had significantly higher symptom burden compared with those with EFnoC across multiple symptoms (fatigue, p = 0.0006; itchy skin, p = 0.0191; emotional impact, p = 0.0073; activity limitations, p <0.0001; cognitive symptoms, p = 0.0012; and social impact, p = 0.0007; Table 1).”

Source: [Marquardt et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13019595/)

<a id="topic-2.2.1.6-8"></a>

### Psychiatric symptoms: anxiety and depression in adults with diagnosed NASH

> “After adjusting for baseline demographics and characteristics, NASH (N = 136) compared to the matched general population cohort (N = 544), reported significantly lower (worse) mental (MCS 43.19 vs. 46.22, p = 0.010) and physical (PCS 42.04 vs. 47.10, p < 0.001) status, higher % with anxiety (37.5% vs 25.5%, p = 0.006) and depression (43.4% vs 30.1%, p = 0.004),”
> “More NASH patients reported anxiety (37.5% vs. 25.5%, p = 0.006) and depression (43.4% vs. 30.1%, p = 0.004), but sleep difficulties did not differ between cohorts (Fig. 2).”

Source: [Tapper et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10077759/)

<a id="topic-2.2.1.6-9"></a>

### Physical examination: features of insulin resistance and of advanced liver disease

> “Body fat distribution (eg, android vs. gynoid, lipodystrophic), features of insulin resistance (eg, dorsal-cervical fat pad, acanthosis nigricans), features of advanced liver disease (eg, firm liver, splenomegaly, prominent abdominal veins, ascites, gynecomastia, spider angiomata, palmar erythema)”
> “Initial evaluation of such patients should include screening for metabolic comorbidities, assessment of alcohol intake, and exclusion of other causes of liver disease as well as physical examination to identify signs of insulin resistance and advanced liver disease (Table 1).”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.6-10"></a>

### Signs of fluid retention, bleeding, and hepatic decompensation

| Physician-reported sign or symptom, n (%) | Overall (n = 424) | AASLD-derived low risk (n = 141) | AASLD-derived indeterminate risk (n = 30) | AASLD-derived high risk (n = 82) |
| --- | --- | --- | --- | --- |
| Swelling in legs, ankles, feet | “42 (9.9)” | “11 (7.8)” | “1 (3.3)” | “20 (24.4)” |
| Swelling of abdomen | “26 (6.1)” | “1 (0.7)” | “0 (0.0)” | “16 (19.5)” |
| Tendency to bleed and bruise more easily | “9 (2.1)” | “1 (0.7)” | “0 (0.0)” | “6 (7.3)” |

Source: [Shinde et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12519272/)

> “The principal outcomes included death from any cause, hepatic decompensation (clinically apparent ascites, overt encephalopathy, or variceal hemorrhage),”
> “Encephalopathy (in 30 patients) and ascites (in 19) were the most common new decompensation events.”

Source: [Sanyal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8881985/)

Additional sources: [Huang et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40050362/)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
